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SUMMARY 
Colon cancer accounts for about 7.9% of all cancer-related deaths worldwide 
(Parkin et al., 2005). Colon cancer is the second most common cancer in both genders in 
Singapore. Despite knowledge of the key molecular players involved in the development 
of colon cancer, the incidence of colon cancer continues to climb steadily. Hence the 
current level of prevention, prognosis and clinical therapy still needs further 
improvement. Metastasis, or the spread of cancer, is the leading cause of mortality in 
cancer patients. Even though the physiological steps of metastasis have been elucidated, 
the specific molecular players that contribute to the progression of cancer to metastasis 
have not been well-defined. The identification of these genes is essential to improve the 
current therapy of metastatic diseases. The first aim of this study is to investigate the 
expression of two closely related isoforms of histone deacetylase enzymes, HDAC1 and 
HDAC2 in colon cancer cases. The second aim of this study is to characterise a set of 
metastatic variant cell lines which had been previously generated in the laboratory. The 
characterisation of the cell lines will involve in vitro and in vivo assays, as well as 
genetic profiling using the microarray technique. 
HDAC1 and HDAC2 are two isoforms of the Class I histone deacetylases. In this 
study, HDAC1 and HDAC2 mRNA and protein levels were shown to be upregulated in 
colorectal cancer. However, the upregulation of HDAC2 was more robust and observed 
more frequently compared to HDAC1. The upregulation of HDAC2 was observed in 
colonic polyps, suggesting that the change occurred early in the carcinogenic process. 
HDAC2 mRNA expression was further increased in the transition from polyp to 
carcinoma. In contrast, the upregulation of HDAC1 in polyps was not as robust. This 
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suggests that despite being highly homologous, HDAC1 and HDAC2 may be regulated 
differently in colorectal polyps and colorectal carcinoma.  
The laboratory has previously generated a set of metastatic variant lines from the 
poorly metastatic HCT116 line through an in vivo passaging method. Two clonal lines 
that were generated, namely C1 and E1, exhibited high invasiveness in an in vitro assay 
and interestingly, slower proliferation rates compared to the rest of the cell lines. E1 was 
also found to have a fibroblastoid morphology, reminiscent of an epithelial-
mesenchymal transition (EMT). Genetic profiling of the parental HCT116 and its 
metastatic variants was carried out using the Affymetrix HG U133A chip. After 
imposing a set of selection criteria, 153 unique genes were identified to be differentially 
regulated in the metastatic variant lines. One of the genes, Caveolin-1 (Cav-1) was 
chosen as the focus of this study. Cav-1 was found to be downregulated in the metastatic 
lines, especially in C1 and E1 lines. Subsequent validation confirmed the Cav-1 
expression at both the mRNA and protein levels. Cav-1 was re-expressed transiently in 
the E1 line as it is least expressed in that line. The re-expression of Cav-1 was able to 
reduce invasiveness of E1 in in vitro assay. These data suggest that Cav-1 plays a role in 
colon cancer invasion and merit further investigation.  
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1 INTRODUCTION 
1.1 Incidence, staging & survival rate of colon cancer 
Colon cancer is the second most common cancer in both gender groups, 
second only to lung and breast cancers in the male and female groups respectively. 
Combining the data in the two gender groups, colon cancer tops the list as the overall 
common cause of cancer in Singapore (Seow, A. et al., 2005). For the past three 
decades, colon cancer incidence has continued to climb steadily at a rate of 0.66 per 
100,000 population per year. This is seen as a disturbing trend as the incidence of 
many other types of cancers is relatively steadying or even declining. The incidence 
rate of colon cancer in Singapore mirrors those observed in the developed countries. 
The five-year survival rate of colon cancer patients vary according to the 
stage of the disease determined at the time of diagnosis. The staging system that is 
commonly used in the current clinical setting is the American Joint Committee on 
Cancer (AJCC) system, also called the Tumour-Nodes-Metastasis (TNM) system. 
Figure 1.1 shows a cross-section of the intestinal tract detailing the multiple layers of 
the colon wall. This figure serves to aid in the understanding of the 'T' staging 
definition of the TNM system, as defined in Table 1.1. The definition of the different 
classifications in the 'N' and 'M' categories are also included in Table 1.2. Table 1.2 
shows the five-year survival rate of patients belonging to the different AJCC/TNM 
stage groupings. All the information pertaining to the AJCC/TNM staging was 
obtained from the American Cancer Society® website.   
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Figure 1.1 A cross-section of the intestinal tract showing the multiple layers of the colon 




Tx No description of the tumour's extent is possible because of incomplete 
information 
Tis The cancer is in the earliest stage. It has not grown beyond the mucosa 
(inner layer) of the colon or rectum. This stage is also known as 
carcinoma in situ or intramucosal carcinoma 
T1 The cancer has grown through the mucosa and extends into the 
submucosa 
T2 The cancer has grown through the submucosa and extends into the 
muscularis propria 
T3 The cancer has grown completely through the muscularis propria into 
the subserosa but not to any neighbouring organs or tissues 
T4 The cancer has spread through the wall of the colon or rectum into 
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Nx No description of lymph node involvement is possible because of 
incomplete information 
N0 No lymph node involvement is found 
N1 Cancer cells found in 1 to 3 nearby lymph nodes 
N2 Cancer cells found in 4 or more nearby lymph nodes 
Mx No description of distant spread is possible because of incomplete 
information 
M0 No distant spread is seen 
M1 Distant spread is present 
 
Table 1.1 Definition of the different TNM classifications. (Information taken from the 
American Cancer Society® website, Oct 2005). 
 
Stage Grouping TNM designation Five-year survival rate 
Stage 0 Tis, N0, M0 100% 
Stage I T1, N0, M0 or T2, N0, M0 93% 
Stage IIA T3, N0, M0 85% 
Stage IIB T4, N0, M0 72% 
Stage IIIA T1-2, N1, M0 83% 
Stage IIIB T3-4, N1, M0 64% 
Stage IIIC Any T, N2, M0 44% 
Stage IV Any T, Any N, M1 8% 
 
Table 1.2 The five-year survival rate of patients according to the TNM staging 
(Information taken from the American Cancer Society® website, and Cancer Update (A  
Publication of the National Cancer Centre of Singapore), Oct 2005. The 5-year survival 
rate data was obtained from (O'Connell et al., 2004)). 
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As it is with any type of cancer, the earlier the stage at which the disease is 
discovered, the better the prognosis for the patient. Table 1.2 clearly reflects this 
notion. The patient may even have a 100% five-year survival chance if the disease is 
discovered very early (Stage 0). Hence, next to prevention, it is imperative to carry 
out early detection of the disease. Much of the molecular mechanisms leading to 
colon cancer development has been elucidated, and this will be further discussed in 
section 1.3.   
It can also be inferred from the Table 1.2 that the most drastic drop in the 
five-year survival rate of the patients occurs between stage IIIC and stage IV 
categories. The five-year survival rate of patients drops to as low as 8% if these 
patients are diagnosed with distant metastasis upon clinical presentation. Metastasis 
is indeed one of the leading causes of cancer-related deaths. Metastasis is a complex, 
multigenic process. Even though the physiological steps in the metastatic cascade are 
well defined, there remains a poor understanding of the underlying basic mechanisms 
involved. Section 1.4 will provide greater insights into understanding the 
physiological steps involved in metastasis. A surprisingly small number of genes 
have been identified in colon cancer that either promote or suppress metastasis. An 
in-depth discussion of these genes will be presented in Sections 1.5 and 1.6. The 
identification of these genes and the elucidation of the mechanisms by which they 
affect the metastatic capability of the cancer cell are keys to a more rational 
treatment of metastatic disease. 
1.2 Molecular mechanisms of colon cancer development 
The multi-step mechanisms of colon cancer development have been well-
characterised and the key molecular players involved have been elucidated. Figure 
Introduction 
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1.1 depicts a well-known genetic model for colorectal tumorigenesis, developed by 
Fearon and Vogelstein (Fearon and Vogelstein, 1990). Colon cancer develops when 
the normal epithelium transits to become adenoma then to carcinoma as a result of 
certain genetic changes. The model was proposed based on studies done to compare 
the genetic changes that occur between normal colon epithelium, adenomas and 
malignancies. The general understanding points to alterations in genes which perturb 
the Wnt pathway as the tumour initiator. There are generally two major pathways 
which lead to colon cancer development. Approximately 85% of colon cancer cases 
result from events which involve chromosomal instability (CIN), while the 
remaining 15% result from events which involve microsatellite instability (MSI). 
Cases involving CIN are characterised with aneuploidy and partial chromosomal 
losses. One particular chromosomal loss occurs at chromosome 5q, giving rise to 
loss-of-function APC mutation, leading to dysregulated Wnt/β-catenin signalling. 
Other genetic alterations that accompany these cases include P53 mutation 
(chromosome 17p), DCC/MADH2/MADH4 mutation (chromosome 18q), and KRAS 
mutation (figure 1.1). It should be noted however, that it is the cumulative effect of 
these genetic changes, rather than their sequential steps, which results in the 
development of colon cancer.  The remaining 15% of colon cancer cases do not 
involve APC mutation and are often found to have activating mutation in β-catenin. 
These cases are also accompanied with mutations in the mismatch-repair (MMR) 
genes, as well as incidence of MSI and diploid phenotype. These cases have very low 















Figure 1.2 A classic genetic model of colon cancer development as proposed by Fearon 
and Vogelstein (Fearon and Vogelstein, 1990). The figure shows the multistep 
progression of colon cancer from the normal epithelium up to the metastatic colon 
tumour. The figure was adapted from Burger’s Medicinal Chemistry & Drug 
Discovery, 6th edition, Vol 5: Chemotherapeutic Agents, Chapter 1: Molecular Biology 
of Cancer. 
 
1.3 Physiological steps of metastasis 
Metastasis is defined as the growth of tumour distant from the site of primary 
neoplasm (secondary growth). Despite having elucidated the major molecular events 
responsible for colon cancer development, the key molecular players which cause 
carcinoma progression to metastasis remain elusive. The physiological process of 
metastasis, however, has been well-characterised. Metastasis occurs in a multi-step 
process whereby specific genetic alterations enable tumour cells to overcome barriers 
to local invasion, intravasation, survival in circulation, arrest in capillaries, 
extravasation, and finally outgrowth to produce macrometastases at distant organs. 
These ‘genetic alterations’ that enable tumour cells to gain metastastic phenotype 
are, unfortunately, less well-characterised. Recent work using intra-vital video 
microscopy (Chambers et al., 2000) has enabled us to gain a better understanding on 
the rate-limiting steps in the metastatic process. Figure 1.3 shows the physiological 
steps of metastasis as well as the efficiency of each of those steps. The overall 
process of metastasis is considered to be inefficient. Intravasation, or the process in 
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which have managed to enter into the circulation will then have to withstand the 
harsh fluidic environment within the vessels, become arrested in distant organs, 
adhere to the vessel wall and begin the process of extravasation. Contrary to previous 
beliefs, survival in the circulation up to the extravasation process are now known to 
be efficient processes (Chambers et al., 2000). Majority of the cells which have 
managed to enter the circulatory system are able to complete the steps up to 
extravasation successfully. The few final steps that follow after extravasation are 
however known to be inefficient and rate-limiting. Survival of cells which have 
extravasated, initial growth of cells which survive the extravasation process, as well 
as subsequent growth to develop into overt metastasis, are now known to be highly 
inefficient processes.  
 
Steps in metastatic process Efficiency 
Intravasation Inefficient 
Survival in the circulation Efficient 
Arrest in organ Efficient 
Extravasation Efficient 
Survival of cells after extravasation Inefficient 
Initial growth of cells after extravasation Inefficient 
Persistence of growth Inefficient 
 
Table 1.3 The physiological steps of metastasis and the efficiency of each of these steps. 
Table adapted from (Chambers et al., 2000) 
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1.4 Genes involved in colon cancer metastasis 
A recent review by Rudmik et. al. published in the Journal of Surgical 
Oncology  provides a good overview of some of the genes that have been associated 
with hepatic metastasis in colorectal cancer (Rudmik and Magliocco, 2005). Even 
though the list of genes reported in the article is by no means exhaustive, it 
represents twenty of the most studied genes based on the number of references 
available in the literature, as well as genes supported by a strong in vivo validation 
data. The genes are divided into four functional categories, namely proteolysis, 
adhesion, angiogenesis and cell survival.  
Two genes fall under the proteolysis category, namely MMP-7 (or 
Matrilysin) and uPA. Matrix metalloproteinase 7 (MMP-7) is found to be 
overexpressed in the majority of colon cancer cases (Nagashima et al., 1997; Newell 
et al., 1994; Yoshimoto et al., 1993) and caused the formation of cell aggregation 
accompanied by enhanced ability to form liver metastases (Kioi et al., 2003). The 
increased expression of MMP-7 is believed to enhance the ability of cancer cells to 
survive an anchorage-independent environment. Urokinase plasminogen activator 
(uPA) is a ligand of uPA receptor (uPAR), which causes the production of plasmin 
upon activation. Plasmin will in turn assist in the degradation of extracellular matrix 
(ECM) and activation of pro-MMPs in the extracellular space. Signalling processes 
involving β1 integrin and Src kinase have also been implicated in the role that uPAR 
plays in enhancing colon cancer metastasis.  
Several integrins, osteopontin (OPN), SRC activation, and carcinoembryonic 
antigen (CEA) all fall under the cellular adhesion category. Integrins act as a relay 
machine by transmitting extracellular signals into activation of intracellular signaling 
processes. Integrins are able to bind to many ECM molecules, causing the activation 
Introduction 
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of downstream intracellular signaling which aid in the cellular adhesion process. 
Osteopontin (OPN) is known to induce integrin-mediated cell survival, motility and 
anti-apoptotic intracellular pathways which enhance the metastatic potential of the 
cells. c-src increases metastatic potential of cancer cells by inducing cell-matrix 
adhesion. A recent study on Carcinoembryonic Antigen (CEA) revealed that it was 
able to modify the hepatic environment to increase the survival rate of colon cancer 
cells which have extravasated there.  
Vascular endothelial growth factor (VEGF) is implicated in the process of 
angiogenesis. It induces cell migration, proliferation, invasion as well as increase 
vascular permeability.  High level of VEGF in primary colon tumour is associated 
with poor prognosis. VEGF is thought to help only in the initial process of liver 
metastasis formation, but not in the maintenance of the overt metastasis.  
The genes which have been shown to alter the ability of colon cancer cells to 
survive in the liver include TRAIL (tumour necrosis factor-related apoptosis-inducing 
ligand), interferon β (IFN-β), inducible nitric oxide synthesis (iNOS), Drg-1 and 
CXCR4 (the receptor of CXC12 chemokine).  
1.5 Metastasis suppressor genes 
 The first metastasis suppressor gene was discovered in 1988 by Steeg et. al., 
in an article published in the Journal of the National Cancer Institute (JNCI) (Steeg 
et al., 1988). The group reported its findings of NM23 gene and its association with 
low tumour metastatic potential in a murine melanoma cell line and rat mammary 
carcinomas. This gene was discovered by a complementary DNA (cDNA) 
subtraction approach. The existence of metastasis suppressor genes was subsequently 
supported by studies done by other groups (Miele et al., 1997; Yang et al., 1997b) in 
Introduction 
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the following years after the discovery of NM23 gene. Majority of the groups utilised 
the microsome-mediated chromosomal transfer (MMCT) technique to identify new 
metastasis suppressor genes. These studies reported the suppression of metastasis in 
in vivo models when specific chromosomes were transferred into metastatic cell 
lines. Yoshida et. al. reviewed and summarised the techniques and validation 
approaches employed in the discovery of some of the metastasis suppressor genes, as 
well as the type of tumours associated with each of the genes (Yoshida et al., 2000).  
 Metastasis suppressor genes have two important characteristics. Firstly, they 
suppress metastasis without affecting the growth of primary tumour. Secondly, they 
are rarely mutated in metastatic cancers; rather, they are often found to be down-
regulated through epigenetic mechanisms or post-translational/transcriptional 
modifications (Yoshida et al., 2000).  
 A recent review by Steeg et al. listed twelve genes which have been identified 
and confirmed to be metastasis suppressor genes, as shown in Table 1.4 (Steeg, 
2004). The table outlines the twelve genes, the cancer cell type associated with each 
gene, as well as their functions. As can be inferred from the table, only three out of 
the twelve genes (DRG-1, KAI1 and NM23) have been associated with colon cancer 
metastasis. Even then, some of their roles in colon cancer metastasis are conflicting 
in the literature. The involvement of KAI1 in colon cancer metastasis was first 
reported by a Japanese group (Takaoka et al., 1998), supported by another group in 
Switzerland (Maurer et al., 1999), but was conflicted a few years later by another 
group (Yang et al., 2002). The association of NM23 with colon cancer metastasis was 
also met with conflicting reports from different groups (Heide et al., 1994; 
Kapitanovic et al., 2004; Myeroff and Markowitz, 1993; Royds et al., 1994). Guan 
et. al. reported that overexpression of DRG1 in metastatic colon cancer cells reduced 
Introduction 
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invasiveness in both in vitro and in vivo assays (Guan et al., 2000; 2005) However, 
the clinical data reported by the group showing undetectable or vastly reduced Drg1 
expression in five clinical samples of colorectal liver metastases was contrasted in 
another report involving a large-scale clinical samples analysis (Shah et al., 2005). 
Hence, none of the three metastasis suppressor genes associated with colon cancer 
has been strongly tested and confirmed. There is thus a great need to identify other 
candidate metastasis suppressor genes associated with colon cancer metastasis. 
 Metastasis suppressor genes open up avenues in the therapy against cancer 
metastasis. Since metastasis suppressor genes are suppressed through epigenetic 
mechanisms and/or post-translational/transcriptional modifications, reactivation of 
the endogenous metastasis suppressor gene expression is potentially achievable. The 
expression of these genes may be returned to its normal level through the use of 
drugs which revert its epigenetic repression and/or post-translational/transcriptional 
modifications.  This approach is relatively simpler and more attainable compared to 
correcting the expression of mutated genes.  
 The development of metastasis requires a concerted expression of many 
different genes (Fidler and Radinsky, 1990; Fidler and Radinsky, 1996). Numerous 
reports have been published detailing the association of many different genes to 
metastasis. However, proving that a certain gene is essential in the development of 
metastasis is much more difficult. Perturbation of the expression of a certain gene 
known to be associated with colon cancer metastasis may often yield negative results 
as its role in metastasis may be replaced by other genes. However, the ability to 
reactivate an endogenous metastasis suppressor gene will mean that it is possible to 
inhibit metastasis by altering the expression of just one gene. Therefore the 
identification of metastasis suppressor genes stand to produce better therapeutic 
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potential compared to genes whose expression are positively correlated to cancer 
metastasis.     
 
Metastasis Suppressor Genes 
Gene Cancer cell type with suppressive activity Functions 
BRMS1 Breast, melanoma Gap-junctional communication 
CLAUDIN4 Pancreas Tight junction protein 
CRSP3 Melanoma Transcriptional co-activator 
DRG1 Prostate, colon Cell differentiation process 
KAII Prostate, breast, colon Integrin interaction, EGFR desensitization 
KiSS1 Melanoma, breast GPCR ligand 
MKK4 Prostate, ovarian MAPKK; phosphorylates and activates p34 and JNK kinases 
NM23 Melanoma, breast, colon, oral squamous cells 
Histidine kinase; phosphorylates KSR, 
which might reduced ERK1/2 
activation 
RhoGDI2 Bladder Regulates RHO and RAC function 
RKIP Prostate Raf kinase inhibitor protein 
SSeCKs Prostate Scaffold protein for PKA and PKC pathways 
VDUP1 Melanoma Thioredoxin inhibitor 
 
Table 1.4 Metastasis suppressor genes which have been identified and the clinico-
pathological cases associated with these genes. 
 
1.6 Microarray studies performed on colon cancer cases 
The advent of microarray as a gene profiling tool was seen as a valuable asset 
in the understanding of the cell biology of human cancers. Its high-throughput nature 
allows scientists to study the expression levels of thousands of genes in numerous 
samples easily. This opens up avenue to improve diagnosis, prognosis and treatment 
of human cancers.   
Recent years have seen a plethora of gene profiling results generated by 
numerous research groups using various platforms, experimental design and 
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analytical methods. In the March 2005 issue of Oncology Reports, Shih et. al. (2005) 
summarised some of the gene profiling data which have been published in the field 
of colorectal cancer alone. They reported that the overlaps in the candidate gene lists 
generated by the different studies remain disturbingly limited, probably due to the 
different platforms used, algorithms applied in the data analysis, type of processing 
done on the tissue samples, location from which the tissue was derived and certain 
bias involved in each study. Only a few of the genes reported were validated, and 
even less was carried on for further downstream work. Genes involved in colon 
cancer metastasis have also been less well-characterised in these studies. 
1.7 Histone deacetylases 
Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are 
enzymes which regulate the acetylation status of the histones, which in turn affect the 
interaction between DNA and transcription regulatory protein complexes, thereby 
regulating the gene expression at the epigenetic level. HAT and HDAC work 
antagonistically. In general, HAT leads to activation of gene transcription, whereas 
HDAC leads to repression of gene transcription. HAT and HDAC have been 
implicated in a few cellular processes like cell proliferation, differentiation and cell-
cycle regulation. Hence, perturbation in the acetylation status has been closely linked 
to the development of cancer (Cress and Seto, 2000). A few HDAC inhibitors are 
now in the clinical trials for their potential role in cancer therapy (Yoo and Jones, 
2006). However, these HDAC inhibitors often have pleiotropic effects as they are not 
specific for the different HDAC isoforms. There are at least 17 mammalian HDAC 
enzymes that have been classified into three major groups. However, the specialised 
functions of the different HDAC isoforms remain largely unknown.  An article 
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published in 1997 by Yang et. al. reported the isolation and characterisation of 
HDAC3 (Yang et al., 1997a). In this article, the group showed a Northern Blot 
analysis of HDAC1, 2 and 3 RNA expression in several tumour cell lines and normal 
human tissues. Interestingly, the colon adenocarcinoma SW480 cell line displayed a 
high expression of HDAC1 and HDAC2, compared to the low expression in the 
normal colon (mucosal lining) tissue. Both HDAC1 and HDAC2 belong to Class I 
HDACs and are shown to be closely associated to each other. In this study, the 
expression of HDAC1 and HDAC2 in colorectal cancer samples was further 
analysed. 
1.8 Objectives of the study 
The first aim of the project was to study the expression of two highly 
homologous and functionally related HDACs, namely HDAC1 and HDAC2, in 
colorectal cancer. The hypothesis to be tested was that HDAC1 and HDAC2 may be 
differentially expressed in colon cancer and may hence play an important role in the 
pathogenesis of colon cancer. The expression levels of HDAC1 and HDAC2 in 
colorectal clinical samples were examined at both the mRNA and protein levels.  
 The laboratory has previously derived a set of metastatic cell lines from the 
poorly metastatic parental HCT116 colon cancer cell line, through an in vivo 
passaging method described by Morikawa et. al. (Morikawa et al., 1988a). The 
second aim of this project was to characterise these derivative cell lines as well as 
validate if they have different levels of metastatic potential. Different in vitro and in 
vivo assays will be employed to characterise these cell lines.  
The third aim of the project was to perform a genetic profiling of the HCT116 
cell line and its derivative lines. The gene expression profiles of the metastatic lines 
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would be compared to that of the parental line using HG U133A chips from 
Affymetrix. This work was made possible by a collaborative effort with Dr Patrick 
Tan of National Cancer Centre Singapore. Each cell line was screened in three 
independent replicates. Genes that were downregulated in the metastatic lines were 
shortlisted as candidate metastasis suppressor genes.  
The fourth aim of the project was to select one candidate metastasis 
suppressor gene for further validation and characterization. A few selection criteria 
were applied and Caveolin-1 was chosen as a candidate metastasis suppressor gene. 
Validation of Caveolin-1 and its possible role in suppressing metastasis was further 
investigated with in vitro experiments. Figure 1.3 summarises the work performed in 
generating the derivative cell lines and the subsequent microarray analysis performed 
on these cell lines. 
The latter four aims of this study were set out to test the hypothesis that the 
gene profiling of cell lines with differing metastatic potential may reveal genes 
involved in the acquisition of a metastatic phenotype. 
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Figure 1.3 Schematic diagram of the derivation of metastastic cell lines from the 
parental HCT116 and subsequent microarray analysis performed. (The figure showing 













HCT116 → M1 → M2 → M3 → D1 → M4  
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2 MATERIALS AND METHODS 
2.1 Investigation of HDAC1 and HDAC2 expression levels in colorectal cancer 
2.1.1 Fresh tissue samples and RNA isolation 
Anonymised samples of fresh tumor and matched normal mucosa  were obtained 
from 16 human colorectal cancers surgically resected between June 1997 to August 
2000 at National University Hospital and Tan Tock Seng hospital, Singapore. Five of 
these sets of samples had concomitant polyps. All samples were frozen and stored in 
liquid nitrogen until the time of ribonucleic acid (RNA) extraction. Histopathology of 
the samples was verified by a pathologist. Total RNA was extracted from these tissues 
by the guanidium thiocyanate method (MacDonald et al., 1987). 
2.1.2 Quantitative real-time RT-PCR 
Real-time reverse transcription-polymerase chain reaction (RT-PCR) was carried 
out using the LightCycler System instrument (Roche, Mannheim, Germany). Amplified 
products were detected by measuring the binding of the fluorescence dye SYBR Green I 
to double-stranded DNA (SYBR Green I RNA amplification kit, Roche). Primers were 
designed and optimised for maximum efficiency and specificity according to 
manufacturer’s specifications. Table 2.1 lists the primer sequences used in the 
experiment. 
The PCR reaction components comprised 2 µl of RT-PCR reaction mix (dNTPs, 
MgCl2, SYBR Green), and 0.2 µl of RT-PCR enzyme mix, a final concentration of 6 mM 
MgCl2, and 0.4 µl of each primer (10 µM), in a total volume of 10 µl. The PCR reaction 
Materials and Methods 
  18 
was started with an initial reverse transcription at 55oC for 10 minutes, followed by 30 
seconds at 95oC and 45 cycles of amplification (0 second at 95oC, 10 seconds at 60oC 
and 9 seconds at 72oC for all primer sets. At the end of each cycle, the fluorescence 
emitted by SYBR Green was measured. After completion of the amplification process, 
samples were subjected to a temperature ramp with continuous fluorescence monitoring 
for melting curve analysis to test for product specificity. The products were analyzed by 
electrophoresis on a 2% agarose gel and verified by sequencing. A serial dilution of 
standards was individually constructed for each set of primers to determine the log-
linear range and the efficiency of the reaction using the LightCycler Data Analysis 
Software. Relative quantification of HDAC1 and HDAC2 in normal, polyp and tumor 
samples was carried out after normalization with 18S, an internal control. Calculations 
were performed according to manufacturer’s specifications.  
 
Table 2.1 Primer sequences used in the quantitative real-time RT-PCR 
 
2.1.3 Tissue Microarray 
A total of 90 colorectal samples (45 sets of tumor and paired normal mucosa) 
were included in this study.  These were random cases from the files of the Department 
of Pathology, National University Hospital of Singapore, with no selection bias 
regarding gender, age, clinical presentation or tumor staging. The materials were fully 
Gene Forward Primer Reverse Primer 
HDAC1 5’-aactggggacctacgg-3’ 5’-acttggcgtgtcctt-3’ 
HDAC2 5’-gttgctcgatgttggac-3’ 5’-ccaggtgcatgaggta-3’ 
18S rRNA 5’-gtaacccgttgaaccccatt-3’ 5’-ccatccaatcggtagtagcg-3’ 
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anonymised prior to the inclusion in the study. The tissue microarrays (TMAs) were 
constructed as before (Zhang et al., 2003), including negative and positive controls in 
the array to assess the adequacy of the staining. After a morphologically representative 
area of tumor was annotated by the pathologist, tissue cylinders with a 0.6 mm diameter 
were punched from the donor tissue block and deposited into a recipient block using a 
tissue arraying instrument (Beecher Instruments®, Silver Spring, MD). A section was 
stained with Haematoxylin and Eosin (H&E) for histological confirmation of the arrayed 
tissues.  Scoring of HDAC1 and 2 expressions in the TMA format was based on the 
intensity of the staining, with 0 score if no staining was detected and 1 to 3 representing 
low, moderate or intense expression (refer to figure 3.2 for an illustration of this 
approach).  
2.1.4 Immunohistochemistry 
Immunohistochemical analysis was performed using a standard indirect 
immunoperoxidase method. Three μm-thick sections of formalin-fixed, paraffin-
embedded tissues were deparaffinised, treated with 3% hydrogen peroxide in Tris-
buffered saline. The sections were then treated with 10 µmol/L citrate buffer (pH 6.0) at 
96oC for 30 minutes. Staining was performed using an avidin-biotinylated horseradish 
peroxidase complex method (DAKO, Glostrup, Denmark). Rabbit polyclonal antibodies 
against HDAC2 and HDAC1 (Santa Cruz Biotechnology, Santa Cruz, CA) were used at 
a dilution of 1:100 and 1:500 respectively.  HDAC1 and HDAC2 antibodies have no 
cross-reactivity with each other as unique regions were used to design each of the 
antigen. Negative controls were performed to ensure the specificity of the antibodies 
used (data not shown). Hematoxylin was used as counterstain. 
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2.1.5 Statistical Test 
Paired-samples T-Test and Chi-square test with Yates’ continuity correction 
were performed using GraphPad Prism Version 4.0. A two-tailed p-value of less than 
0.05 was considered statistically significant. 
2.2 Characterisation of HCT116 and its derivative lines 
2.2.1 Cell culture and reagents 
The human colon cancer cell line HCT116 was purchased from ATCC 
(Bethesda, MD, USA). The HCT116 cell line and its metastatic derivatives were 
cultured in McCoy’s 5A Modified medium (Sigma-Aldrich, St Louis, MO, USA) 
supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA). Cells 
were grown at 37°C in a humidified incubator supplemented with 5% CO2.  
2.2.2 Establishment of metastatic variants from HCT116 cell line 
Five-week-old female athymic mice were purchased from Animal Resources 
Centre (Canning Vale, WA, Australia) and maintained under specific pathogen-free 
conditions. The in vivo selection procedure used for the generation of metastatic variants 
from HCT116 colon cancer cell line has been described previously (Morikawa et al., 
1988a). Briefly, 2x106 cells suspended in 0.05ml of 1X PBS (Phosphate Buffered 
Saline) were injected into the medial spleen tip. Six to eight weeks after injection, the 
animals were sacrificed and post-mortem examination performed. The hepatic metastatic 
nodules were obtained, washed in McCoy’s 5A Modified medium containing 10% FBS, 
100U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B, and 
minced. Following an incubation with 50U/ml dispase I for 30 - 60 minutes at 37oC, the 
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dispersed cells were filtered through a 100 µm filter. The cell line obtained from the 
hepatic metastatic nodules after the first passage was named M1. The procedure of in 
vivo selection was repeated twice to obtain M2 and M3 cell lines. Clonal lines C1, D1 
and E1 were isolated from the M3 cell line using the limiting dilution technique. The D1 
clonal line was used for another round of in vivo selection to generate the M4 cell line. 
The HCT116 derived cell lines were characterised for their metastatic ability by 
injecting 1x106 cells into the medial spleen tip of nude mice and the number of liver 
metastases nodules counted 8 weeks after injection, unless moribund state is reached 
earlier than the stipulated time. After post-mortem examination, the spleen, liver and 
lung tissues were fixed in 4% formaldehyde solution overnight, and processed for 
paraffin embedding. The paraffinised tissues were stored at -20°C prior to sectioning 
and immunohistochemical analysis. 
2.2.3 Tissue Samples and RNA isolation 
Two anonymised matched samples of colonic normal, tumor and liver metastasis 
tissues were obtained from human colorectal cancers surgically resected at the Tan Tock 
Seng Hospital, Singapore. All samples were snap-frozen and stored in liquid nitrogen 
until ribonucleic acid (RNA) extraction. Histopathology of the samples was verified by a 
pathologist. Total RNA was extracted from the tissues using the TRIZOL® (Invitrogen, 
California, USA) reagent, according to the manufacturer’s specifications. RNA from 
another four cases of such matched samples was obtained as part of a collaborative work 
with M.T. (University Health Network, Ontario Cancer Institute, Ontario, Canada). 
Informed patient consent was obtained for all of the cases. The use of these tissue 
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samples in this project was approved by the National University of Singapore 
Institutional Review Board (NUS IRB). 
2.2.4 alamarBlue™ proliferation assay 
Two thousand cells of each cell line were plated into each well of a 96-well plate 
in hexaplicates, after which alamarBlue™ reagent (Serotec Ltd, Oxford, UK) was added. 
The cells were incubated at 37°C in a humidified incubator supplemented with 5% CO2. 
Spectrophotometric readings were taken at wavelengths of 570nm and 600nm at the 
indicated time-points in the 72-hour incubation period. The percentage reduction in the 
readings, which is reflective of the proliferation rate of the cells, was calculated using a 
formula specified by the manufacturer and plotted against the specific time-points. The 
data presented is representative of three independent experiments. 
2.2.5 In vitro invasion assay 
BD Matrigel™ basement membrane matrix (BD Biosciences, USA) was diluted 10-fold 
and coated on the upper chamber membrane (pore size 8.0µm) in 6.5mm diameter 
transwells (Corning Costar, USA). Cells were harvested by trypsinization and plated on 
the upper chamber of each transwell at a density of 5x104 cells in 100µl of serum-free 
McCoy’s 5A modified media. Transiently transfected cells were harvested at 24 hours 
post-transfection for the in vitro invasion assay. Complete McCoy’s 5A modified media 
was added to the lower chamber. The transwells were incubated at 37°C in a humidified 
incubator supplemented with 5% CO2 for 48 hours, after which the cells in the upper 
chamber were removed and the upper-side of the membrane thoroughly cleaned. Cells 
that have invaded through the matrigel-coated membrane were stained with crystal 
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violet and imaged at 25x magnification. 3 independent experiments were carried out in 
triplicates for each condition. 
2.2.6 Cell growth in ultra low cluster plates 
1x105 cells of each cell line were plated in a 24-well Ultra Low Cluster plates 
(Costar, Corning Inc, NY, USA) in 500μl of complete media. The cells were observed 
and pictures taken 24 hours after plating. 
2.2.7 RNA isolation from cell lines 
Total RNA was extracted from cell lines using the Qiagen RNeasy Mini Kit® 
(Qiagen, Hilden, Germany). RNA was quantified photometrically at 260nm 
2.2.8 Quantitative real-time RT-PCR 
Quantitative real-time RT-PCR was performed using the LightCycler® instrument with 
the SYBR Green I RNA amplification kit (Roche Diagnostics, Mannheim, Germany), as 
described in section 2.1.2. The primer sequences used are listed in table 2.2. 
 
Table 2.2 Primer sequences used in the quantitative real-time RT-PCR 
Gene Forward Primer Reverse Primer 
Cav-1 5’-cgaccctaacacctca-3’ 5’-gaatggcgaagtaaatgc-3’ 
HPRT1 5’tgacactggcaaaacaatgca3’ 5’ggtccttttcaccagcaagct3’ 
18S rRNA 5’-gtaacccgttgaaccccatt-3’ 5’-ccatccaatcggtagtagcg-3’ 
Palladin 5’-tggtgcgtgagaacgg-3’ 5’-cccaatacacgacattcc-3’ 
S100A4 5’-acgctgtcatggcgt-3’ 5’-cgttacacatcatggcgatgc-3’ 
GAPDH 5’-agcaatgcctcctgcaccaccaac-3’ 5’-ccggaggggccatccacagtct-3’ 
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2.2.9 Microarray data collection and analysis 
Microarray analysis was performed on the HCT116 cell line and its 7 metastatic 
derivatives using Affymetrix HGU133A chips (Affymetrix Inc, Santa Clara, CA, USA). 
RNA extracted from the cell lines were processed according to protocol outlined in the 
Affymetrix technical manual. Three chips were used for each of the cell lines. 
MicroArray Suite 5.0 (MAS) (Affymetrix Inc, Santa Clara, CA, USA) was used for the 
initial analysis of the scanned images. For absolute (this is the term used, according to 
Mani) analysis, each chip (n=3) was scaled to a target intensity of 500 and probe sets 
were assigned a signal intensity and detection call of “Present, Marginal or Absent”. The 
absolute data (signal intensity, detection call and detection P-value) were exported into 
GeneSpring v7.2 (Silicon Genetics, Redwood City, CA, USA) software for further 
analysis by parametric test based on the crossgene error model (PCGEM). Firstly, all of 
the measurements on each chip were divided by the 50th percentile value (per chip 
normalization). Secondly, each gene was normalised to the baseline value of the control 
samples (per gene normalization) using the mean. Genes from "all genes" with 
expression control signal greater than 20 in at least 5 of 11 conditions were selected. 
Genes ‘Present’ or ‘Marginal’ in at least 6 of 33 samples were then selected. 
Subsequently, the genes were filtered on a fold change of 2 against controls in at least 
one of 7 conditions. ANOVA approach was used to find differentially expressed genes 
(p<0.05) and the Bonferroni multiple testing correction was applied. Finally, data 
representing replicates of the same experimental condition were averaged. The 
differentially expressed genes were annotated according to Gene Ontology-Biological 
process and further clustered using GeneSpring 7.2 software. 
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2.2.10 Immunohistochemical analysis 
Immunohistochemical analysis was performed using a standard indirect 
immunoperoxidase method. 3μm-thick sections of formalin-fixed, paraffin-embedded 
tissues were deparaffinised, treated with 3% hydrogen peroxide in Tris-buffered saline 
and pre-treated with Antigen Unmasking Solution (Vector Laboratories, California, 
USA) at 95oC for 10 minutes. Staining was performed using an avidin-biotinylated 
horseradish peroxidase complex method (DAKO, Glostrup, Denmark). Rabbit 
polyclonal antibody against Cav-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
was used at a dilution of 1:200, with overnight incubation at 4 oC. Hematoxylin was used 
as counterstain. 
2.2.11 Construction of Cav-1 expression vector 
Full-length cDNA encoding human Cav-1 was amplified by RT-PCR from 
HCT116 mRNA. The primers used were Cav-1 forward 5’-CTGGCTAGCGCCGCC 
ATGTCTGGGGGCAAATA-3’ and Cav-1 reverse 5’-CGGGATCCTTATATTTCTTTC 
TGCAAGTTGA-3’. The primers were designed to contain appropriate restriction sites 
for cloning. In addition, the forward primer contained a consensus Kozak sequence 
GCCGCC placed upstream of the translation initiation (ATG) site. The cDNA fragments 
were subsequently cloned into the pcDNA3.1/Zeo(+) vector (Invitrogen Life 
technologies, USA) at the NheI and BamHI restriction sites. The fragment in the vector 
was sequenced to ensure fidelity of amplification and to exclude mutations. 
2.2.12 Transient transfection of Cav-1 in E1 cell line  
1.5x106 cells were plated in a six-well plate in complete media. Transient 
transfection of the Cav-1 vector and the empty vector was carried out 24 hours after 
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plating using Lipofectamine2000 reagent (Invitrogen Life Technologies, Carlsbard, CA, 
USA). The transfected cells were harvested at 48 hour post-transfection and proteins 
were extracted as described in section 2.2.13. 
2.2.13 Western blot analysis 
Total protein extraction was carried out using lysis buffer (6M urea, 1% 2-
mercaptoethanol, 50mM Tris buffer pH 7.4, 1% SDS in phosphate-buffered saline pH 
7.4). 5 µg of total protein was subjected to SDS-PAGE on a 4% stacking gel and 12% 
resolving gel for the analysis of Cav-1 and GAPDH expressions. Proteins were 
transferred to a nitrocellulose membrane (Hybond C-Extra, Amersham Biosciences, UK) 
and blocked overnight in PBS solution containing 0.1% Tween 20 and 5% (w/v) non-fat 
milk powder.  The membrane was then incubated with anti-Cav-1 (Santa Cruz 
Biotechnologies, Inc, Santa Cruz, CA) and anti-GAPDH (Chemicon International, Inc, 
Ternecula, CA) antibodies for 1 hour and subsequently with an anti-rabbit or an 
antimouse secondary antibody. SuperSignal® West Dura (Pierce Biotechnology, Inc, 
Rockford, IL) chemiluminescent substrate was used to detect the bound antibodies. The 
membrane was then exposed to Kodak BioMax film (Eastman Kodak, Rochester, NY). 
2.2.14 Statistical Test 
One-way ANOVA with Bonferroni’s Multiple Comparison Test were performed 
on the quantitative real-time RT-PCR data on Cav-1, using GraphPad Prism Version 4.0. 
A p-value of less than 0.05 was considered statistically significant. 
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3 RESULTS 
3.1 HDAC1 and HDAC2 expression is increased in colorectal tumours 
3.1.1 HDAC1 and HDAC2 mRNA expression is increased in colorectal tumours 
The mRNA expression of HDAC1 and HDAC2 in sixteen matched samples of 
normal colonic and tumour tissues was quantified using real-time quantitative RT-PCR 
LightCycler®system. Five of the 16 sets of samples had concomitant polyps, which were 
also examined for both HDAC1 and HDAC2 mRNA expression. Housekeeping18S 
mRNA was used as a loading control. The specificity of the respective RT-PCR 
products was confirmed using melting curve analysis as well as sequencing (data not 
shown). The results for each matched samples are shown in Figure 3.1 and summarised 
in Table 3.1.  
Only HDAC2 was significantly upregulated in matched colon tumour compared 
to normal mucosa (p<0.05). HDAC2 was upregulated by at least 2-fold in 9/16 tumor 
samples compared to matched normal mucosa. Four of the sixteen samples showed 
upregulation of HDAC2 by at least 5-fold. HDAC2 was upregulated by more than 8-fold 
in 3 tumor samples. Three of the five polyps showed greater than 2-fold upregulation of 
HDAC2 mRNA compared to normal mucosa. HDAC2 was upregulated by 12-fold in 
one of the polyp samples. 
In contrast, only 6/16 showed a more than 2-fold upregulation of HDAC1. 
Moreover, none of the tumour tissues examined showed HDAC1 upregulation greater 
than 4-fold. In the polyp samples, only 2 of the 5 polyps showed more than 2-fold 
upregulation of HDAC1.   
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Figure 3.1 mRNA expression of HDACs 1 and 2 in sixteen matched samples, quantified 
using the real-time RT-PCR LightCycler® system. The vertical axis represents the 
tumour/normal (T/N) ratio calculated for each matched samples, after normalization with 




Table 3.1 Summary of the expression of HDACs 1 and 2 in colorectal cancers and polyp 
samples. The tumour/normal (T/N) and polyp/normal (P/N) ratios were calculated for each 
of the 16 and 5 matched samples respectively. The results were then categorised into two 
groups showing >2-fold and >5-fold increase in expression. * indicates statistical 
significance (p<0.05), calculated using the paired t-test.  
 HDAC1 (T/N) HDAC2 (T/N) HDAC1 (P/N) HDAC2 (P/N) 
> 2-fold 6/16 (37.5%) 9/16 (56.3%) * 2/5 (40%) 3/5 (60%) 
> 5-fold 0 4/16 (25%) 0 1/5 (20%) 
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3.1.2 HDAC1 and HDAC2 protein expression is increased in colorectal tumours 
A tissue array was constructed from 45 matched samples of colorectal cancer and 
normal mucosa. The adequacy of the array was analyzed and all the tissue punches were 
scored by a pathologist (M.S.T) according to the specifications stated in Materials and 
Methods. In particular, the duplicate tissue array of 0.6mm-diameter punches showed 
maximal (>95%) representativity of the intended tumor-normal samples. Figure 3.2 
illustrates a representative protein expression grading for both HDAC1 and HDAC2. 
Tables 3.2a and 3.2b show a summary of the grading intensities of the 45 matched pairs 
of samples expressed as percentages.  
The number of normal mucosal samples distributed in each of the grading 
intensities were similar for HDAC1 and HDAC2, suggesting that basal expression of the 
two proteins were similar in normal colonic mucosa. However, HDAC2 expression in 
tumors was higher compared to HDAC1. Sixty percent of the tumors were scored grade 
3 for HDAC2 expression compared to 45% for HDAC1. Comparing normal mucosa and 
matched tumor samples, there was a 60% increase in the number of samples scoring 3 
for HDAC2 compared to a 37% increase for HDAC1. Interestingly, 12.3% of the tumor 
samples had a score of 0 for HDAC1. None of the tumor samples were scored 0 for 
HDAC2 expression. The difference in HDAC1 and HDAC2 expression in tumors was 
more obvious when the differences in grading between tumor and matched normal 
mucosal samples were compared (Table 2c). There were significantly more tumor 
samples showing at least 2-grade increase in intensity for HDAC2 staining compared to 
HDAC1 (p<0.05). Results of this HDAC study, performed together with a fellow 
graduate student, Huang Bao Hua was recently published (Huang et al., 2005). 
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Grade 0                     Grade 1                    Grade 2                   Grade 3  
 
Figure 3.2 Immunohistochemical analysis on colorectal tissue microarray (TMA).  
Representative examples of the scoring performed on HDACs 1 and 2 staining. Grade 0 is 
defined as negative staining of the nucleus, while grades 1 to 3 represent increasing 
intensity of nuclear staining. The upper panel shows X20 magnification while the lower 
panel shows X600 magnification. 
 
HDAC1 0 1 2 3 
N 24.1 53.7 14.8 7.4 
T 12.3 15.4 27.7 44.6 
 
HDAC2 0 1 2 3 
N 35.0 50.0 15.0 0.0 
T 0.0 12.7 27.0 60.3 
 
 ≤1 ≥2 
HDAC1 59.7 40.3 
HDAC2 38.9 61.1* 
 
Table 3.2 Summary of HDAC1 and HDAC2 scores obtained for the TMA samples. 
Percentage of normal and tumour samples scored in each category for HDAC1 (a) and 
HDAC2 (b). (c) shows percentage of samples showing an increase of ≤1 and ≥2 in scores for 
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3.2 Derivation and characterization of metastatic cell lines from the poorly 
metastatic HCT116 colon cancer cell line 
3.2.1 Isolation and selection of metastatic cell lines from HCT116 cell line 
Poorly metastatic HCT116 colon cancer cells were injected into the spleen of 
Balb/C athymic (nude) mice. The resulting metastatic liver nodules were harvested 
under sterile conditions six to eight weeks after injection. The nodules were 
enzymatically dissociated and expanded in culture for further cycles of in vivo selection. 
The cell lines derived from the first, second and third selection-isolation cycles were 
named M1, M2, and M3 respectively. Single clones were then isolated from M3 cell line 
by means of limiting dilution. Three such clones were obtained, namely C1, D1 and E1. 
Clone D1 was used for another selection-isolation cycle in the nude mice, to generate 
the M4 cell line. It was observed that with each successive cycle of in vivo passaging, 
there was an increase in the resulting liver metastasis nodule, signifying increasing 
metastatic propensity of the cell lines. Liver metastasis were obtained in 7 out of 10 
mice injected with HCT116, with a mean of 1.5 and 3 nodules per mouse sacrificed six 
and eight weeks after injection respectively. In comparison, all 6 mice injected with the 
M2 cell line produced liver metastasis with a mean of 16 nodules per mouse. In mice 
injected with D1, all 4 mice produced liver metastasis with two of them numbering more 
than a hundred. The data are summarised in Table 3.3. The work of generating these 
metastatic derivative cell lines was performed by a previous graduate student in the 
laboratory, Ni Hongmin.  
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Cell line Time of Autopsy (Weeks) 
Average no. of liver metastasis nodules 
(no. of nodules in individual mouse) 
HCT116 8 1.5 (2, 2 ,2, 3, 0, 0) 
M2 8 16 (40, 37, 6, 5, 5, 3) 
HCT116 6 3 (0, 2, 5, 5) 
D1 6 Numerous (5, 14, >100, >100) 
 
Table 3.3 Number of resulting liver metastasis nodules in nude mice injected with the 
respective cell lines, six to eight weeks after injection. The third column shows the average 
number of liver metastasis nodules obtained in the nude mice, with individual mouse data 
provided within the brackets.  
 
3.2.2 In vivo characterisation of the cell lines 
The metastatic potential of the established cell lines were characterised in vivo 
by splenic injection into nude mice. The mice were sacrificed six to nine weeks after 
injection, and the resulting liver metastasis nodules were counted. The variation in the 
length of time the mice were allowed to live after injection may be explained by 
incidents of mice becoming too moribund or when the tumour burden exceeded 10% of 
its initial body weight, before the scheduled sacrifice date. HCT116, M1, M2, M3 and 
E1 cell lines were used in the in vivo characterisation, and the data are summarised in 
table 3.4.  None of the mice injected with HCT116 cells developed liver metastasis 
numbering more than 30 nodules. In fact, 9 out of 12 mice injected with HCT116 cells 
failed to develop any liver metastasis by the time they were sacrificed. One of the 5 mice 
injected with the M1 cells developed liver metastasis numbering greater than 30 
nodules, 5 out of 6 mice did so in M2 cells, 4 out of 5 in M3 cells. In a separate 
experiment, clone E1 was also tested for its in vivo metastatic potential, and 6 out of 8 
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mice injected with E1 cells produced liver metastases. Figure 3.3 depicts three 
representative gross pictures of the resulting liver metastasis obtained in the nude mice, 
six to nine weeks after injection with the respective cell lines. 
After the mice were sacrificed and examined for incidence of metastasis, the 
spleen, liver and lungs were fixed in 4% formaldehyde and processed for paraffin 
embedding. 3μm thick sections were cut from the paraffin tissue blocks and processed 
for H&E staining. Representative pictures of the primary tumour obtained in the spleen 
as well as the liver metastasis nodules are shown in figure 3.4. Hematoxylin gives rise to 
blue nuclear staining, while eosin gives rise to a reddish-pink cytoplasmic staining. The 
histopathology of these sections was verified by a pathologist (M.S.T.). The tumours 
that developed in the spleen and the liver were shown to be adenocarcinoma, verifying 
that they were derived from the injected cells. 
 
 
Table 3.4 Summary of the number of liver metastasis nodules obtained in the in vivo 
characterisation of HCT116 cell line and its derivative cell lines. 
 
 
No. of liver metastatic nodules Cell 
lines n 0 1 ≤ x < 5 5 ≤ x < 30 x ≥ 30 
HCT 12 9 1 2 0 
M1 5 3 0 1 1 
M2 6 0 1 0 5 
M3 5 1 0 0 4 
E1 8 2 3 1 2 
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Figure 3.3 Three representative gross pictures of the resulting liver metastasis nodules 
obtained in nude mice injected with the respective cell lines.  
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Figure 3.4 Representative H&E staining of primary tumour obtained in the spleen (upper 
panel) and its matched liver metastasis (lower panel) in a nude mouse. The histopathology 
of the tumour in both sites were shown to be adenocarcinoma. 
 
3.2.3 In vitro Characterisation of Metastastic Variant Cell Lines 
3.2.3.1 Morphological characteristics of the cell lines 
The derivative cell lines were observed to have similar morphology to HCT116 
when grown in culture, except for E1 cell line. The morphology of the cell lines grown 
in monolayer culture was observed using a phase-contrast microscope. HCT116 cell line 
grew as closely packed polygonal-shaped cells in culture. The E1 clonal line, on the 
other hand appears to have a more flattened and elongated morphology (fibroblastoid), 
reminiscent of mesenchymal cell morphology. This fibroblastoid morphology of E1 was 
retained even when the monolayer culture reached higher density. Figure 3.5 shows 
representative pictures of HCT116 and E1 cell lines grown in monolayer culture, in a 
low and high density environment.  
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Figure 3.5 Representative phase-contrast images showing the morphology of HCT116 cell 
lines grown in monolayer culture, in a low (upper panel) and high (lower panel) density 
respectively (320X magnification). 
 
3.2.3.2 Anchorage independent growth assay 
The parental HCT116 cell line and all of its metastatic variants were grown in a 
low-cluster plate and observed for their ability to grow in suspension (anchorage-
independent environment). The cells were observed for 96 hours. To study the level of 
apoptosis in the population of cells, the sub-G1 population was analysed by propidium 
iodide (PI) staining. All cell lines exhibited very low sub-G1 population and there was 
no significant difference in the level of sub-G1 population among the HCT116 parental 
line and its metastatic variant lines (data not shown). Interestingly, HCT116 was 
HCT116 E1 
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observed to grow in a very tight clump in the low cluster plate, while the metastatic 
variant E1 line displayed less clumping. This observation showed that the E1 displays 
weaker cell-to-cell interactions compared to HCT116. In fact, when the cell clumps were 
mechanically forced to disperse by means of pipetting, the same cell-to-cell interaction 
trend was observed. While it was nearly impossible to disperse the HCT, M1, and M2 
cell clumps, the rest of the metastatic cell line clumps (M3, M4, C1, D1, E1) were fairly 
easily dispersed to varying degrees, with E1 cell clump being the most easily dispersed.  
 
 




















Figure 3.6 Representative pictures of the different cell lines grown in low-cluster plates, 
viewed by a phase-contrast microscope (X100 magnification). The figure depicts the cell 
clumps formed by each cell line before (left panel) and after (right panel) mechanical 
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3.2.3.3 Cell Proliferation Assay 
Using the alamarBlue® assay, the proliferation rate of all the cell lines were 
monitored for 76 hours. The cell lines displayed similar proliferation rate for the first 48 
hours, and thereafter C1 and E1 were seen to display slower proliferation rate compared 
to the rest of the cell lines. This trend was observed in all of the three independent 
experiments performed. Each independent experiment consisted of six replicate 
readings. Figure 3.7 shows a representative result of one experiment. 
 
Figure 3.7 A representative result of the alamarBlue® cell proliferation assay.  
  
3.2.3.4 Transwell Invasion Assay 
The invasive ability of all the cell lines in in vitro system was compared using 
matrigel-coated Transwell® system. Among the cell lines, only M2, C1 and E1 lines 
displayed a significantly higher invasiveness in the Matrigel-coated Transwell®  system 
Alamar Blue Proliferation Assay
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(HCT and E1 shown). Not all metastatic variants exhibited invasive property in this 
assay as their metastatic propensity may be explained by inherent properties other than 
invasiveness. Figure 3.8 shows a representative picture of the invasion assay data 
obtained for all of the cell lines. The picture depicts crystal violet-stained cells that have 
invaded through the Matrigel-coated pores of the Transwell® membrane. The data 




Figure 3.8 Representative result of invasion assay performed on the cell lines using the 
Transwell® system. The figure shows crystal violet-stained cells that have managed to 
invade through the Matrigel-coated pores of theTranswell® membrane. 
 
3.3 Gene profiling of HCT116 and its metastatic variant cell lines 
3.3.1 Microarray analysis  
A mircroarray analysis on HCT116 and its metastatic derivatives were performed 
in a collaborative effort with Dr Patrick Tan of National Cancer Centre Singapore 
HCT116 M2 M3 M1 
M4 D1 E1 C1 
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(NCCS). The microarray screening was performed in three independent replicates for 
each of the cell lines using HG U133A gene chips from Affymetrix. The data was 
analysed in collaboration with Jayapal Manikandan and Dr Alirio Jose Mendelez of 
Physiology Department, NUS. The analysis method is detailed in the methods section. A 
few selection criteria steps were applied to generate a list of genes which were 
differentially expressed in the metastatic cell lines compared to the parental HCT116 
cell line. The criteria excluded genes with very low expression signals and selected for 
genes which demonstrated at least a two-fold change in one or more of the seven 
metastatic variant lines compared to HCT116. These genes were then subjected to 
statistical analysis to determine their significance at p<0.05. Figure 3.9 shows a heatmap 
generated by the GeneSpring software showing 153 unique genes (193 unique probes) 
differentially expressed unique genes that met these criteria.  Apparent changes in the 
gene expression were observed as early as in the M1 line. The gene expression of M1, 
M2 and M3 were generally similar. A unique pattern of gene expression was seen in the 
C1, D1 and E1 clonal lines. M4, which was derived from the D1 clonal line showed 
similar pattern of gene expression. From the 153 unique genes identified, 44 genes were 
found to be either (i) similarly and significantly regulated across most of the metastatic 
variant lines or (ii) similary and significantly regulated in the most invasive cell lines C1 
and E1. Four of these 44 genes have been previously associated with either metastasis or 
EMT, namely, S100A4 (Garret et. al., 2006), TIAM1 (Minard et. al., 2005), PLEC1 
(Steeg et. al., 2005; Montel et. al., 2005) and JAG1 (Veeraraghavalu et. al., 2006).  
Results 
  41 
HCT M2 M3M1 M4 C1 D1 E1  
 
 
Figure 3.9 A heatmap showing cluster diagram of 153 unique genes that met the selection 
criteria. Triplicate chips were used for each cell line. The expression index for each gene 
(row) in each sample (column) is indicated by a color code shown next to the diagram. Blue 
shades represent a downregulation and red shades an upregulation in gene expression 
relative to the parental HCT116 cell line.  
 
3.3.2 Validation of microarray result using real-time quantitative RT-PCR 
The microarray result was validated using real-time quantitative RT-PCR 
LightCycler system. The mRNA expression of three genes, namely caveolin-1, palladin, 
and S100A4 were quantified for this validation purpose. The results of the RT-PCR 










Figure 3.10 The relative mRNA expression levels of Cav-1, Palladin and S100A4 obtained 
in the microarray run (left panel) were validated using real-time qRT-PCR (right panel). 
The qRT-PCR results were consistent with the microarray data. 
Cav-1
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3.4 Caveolin-1 as a candidate metastasis suppressor gene in colon cancer 
Caveolin-1 was chosen as a candidate metastasis suppressor gene in colon 
cancer. The protein level of Cav-1 in the metastatic cell lines were validated using 
Western Blot analysis and the data are shown in figure 3.11. Based on the Western Blot 
result, E1 clonal line was shown to have the least Cav-1 expression, followed by C1 
clonal line. This result is consisten with the qRT-PCR Cav-1 data shown in figure 3.10. 
 
Figure 3.11 Western Blot result showing Cav-1 expression in HCT116, M3, C1, D1 and E1 
cell lines. GAPDH was used as a loading control. 
 
To investigate if Cav-1 level is also downregulated in the clinical samples,  real-
time quantitative RT-PCR was performed on six matched samples of normal colonic 
tissue, colon tumour as well as liver metastasis. The results are summarised in figure 
3.12.  Based on the data, the mRNA expression of Cav-1 was shown to be significantly 
downregulated in the liver metastasis samples when compared to the corresponding 
normal tissue (p<0.01) and colon tumour samples (p<0.05) (indicated by *). The 
downregulation of Cav-1 mRNA in the tumour samples was not found to be statistically 
significant when compared to the corresponding normal samples.   





















Figure 3.12 Summary of relative mRNA expression levels of Cav-1 quantified by real-time 
qRT-PCR in six matched samples of colonic normal, tumour and liver metastasis samples. 
18S was used as a loading control. One-way ANOVA with Bonferroni post-hoc test were 
used in the statistical analysis. * indicates statistical significance (p<0.05), bar represents 
SEM. 
 
To investigate if the downregulation of Cav-1 in the clinical samples also occur 
at the protein level, immunohistochemical analysis of Cav-1 was performed in 16 
matched samples of normal colon, colon tumour and liver metastasis tissue sections. 
These samples were treated under similar conditions of fixation, embedding and storage. 
Figure 3.13 shows representative pictures of the Cav-1 staining obtained in matched 
samples of colonic normal, tumour and liver metastasis. Brown staining indicates 
positive staining. Hematoxylin was used as a counterstain. Negative controls were 
performed to ensure the specificity of the staining (data not shown). The sixteen 
matched samples were graded with a score of 0 to 3, corresponding to a negative and a 
strongly positive Cav-1 staining respectively. The grading was done by a pathologist 
(MST). In normal colon, 94% of the samples showed grades 2-3 staining, and the 
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of the samples showed grades 2-3 staining. In liver metastases, the expression of Cav-1 
was mostly reduced, with 53% of them showing grades 0-1 staining (Figure 3.14).  
 
Figure 3.13 Representative figures showing Cav-1 immunohistochemcical staining in 
matched samples of colonic normal (left panel), tumour (middle panel), and liver 
metastasis (right panel) (X200 magnification). Blue hematoxylin was used as counterstain.  
 
Figure 3.14 Summary of the grading obtained in sixteen matched samples of colonic 
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3.5 Caveolin-1 overexpression decreases invasiveness in E1 cell line 
An overexpression study was performed to investigate if Cav-1 re-expression has 
any effect on the phenotypic characteristics of the metastastic variants. Cav-1 transient 
overexpression was carried out in E1, which has the lowest expression of Cav-1 among 
all the cell lines. The level of Cav-1 overexpression was validated using Western Blot 
method. Figure 3.16 shows partial restoration of Cav-1 expression in E1 cell line 48h 
after transient transfection. The invasive property of E1 overexpressing Cav-1 was 
compared to that of the vector-transfected E1 using Matrigel-coated Transwell system. 
The results showed that partial restoration of Cav-1 expression in E1 reduces its 
invasiveness (Figure 3.17).  
 
Figure 3.15 Western Blot showing partial restoration of Cav-1 expression in E1 cells, 48 
hours after transient transfection was carried out. GAPDH was used as a loading control.  
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Figure 3.16 Representative figure showing reduced invasiveness in E1 upon partial 
restoration of Cav-1 expression. The figure shown is representative of three independent 
experiments comprising of three replicates each. E1 VC: E1 cells transfected with the 





HCT E1 VC E1 Cav-1 
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4 DISCUSSION 
4.1 HDAC1 and HDAC2 expression is increased in colorectal cancer 
HDAC enzymes play a role in the regulation of cell proliferation, apoptosis and 
cell cycle. However the exact roles that they play in those cellular processes are not 
clearly understood. In general, HDAC results in the compaction of the chromatin 
structures, making them inaccessible for the binding of transcriptional factors. Many 
studies have reported the involvement of HDACs in the development of cancer as 
aberrant acetylations status contributes to changes in the normal cellular processes. A 
number of HDAC inhibitors are now in the preclinical or clinical trials to assess the 
efficacy of their antitumour effect. Again, the specific mechanisms by which HDAC 
inhibitors mediate the antitumour effect remain poorly understood. In general, HDAC 
inhibitor exerts its effects by inhibiting the activity of endogenous HDAC enzymes, 
thereby causing an increase in the acetylation status of the histone complexes. This 
increase in acetylation status is believed to result in some changes in gene expression, 
which in turn correct for cellular processes which were defective in the cancer cells. One 
of the major problems posed by the current HDAC inhibitors is the lack of specificity, or 
pleiotropic effects seen in clinical settings. In fact, none of the HDAC inhibitors 
currently available is specific for any isoform of HDAC. This highlights the need to 
identify specific HDAC isoforms with defined roles in the different types of cancer. In 
this way, an HDAC inhibitor specific for one isoform of HDAC could be designed and 
tested for its potency and specificity. 
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In this study, the expression levels of HDAC1 and HDAC2 were examined in 
colon cancer tissues. HDAC1 and HDAC2 are two closely related enzymes belonging  
to the Class I group. HDAC 1 and HDAC2 share 75% identity in DNA sequence and 
85% identity in protein sequence (Taunton et al., 1996; Yang et al., 1996), and are often 
found together in protein complexes. Despite their close relationship, the results from 
this study has shown some differences in the role that HDAC1 and HDAC2 may play in 
the development of colon cancer.  
Results from this study have shown that HDAC1 and HDAC2 mRNA and 
protein levels were upregulated in colorectal cancer. However, the upregulation of 
HDAC2 was more robust and observed more frequently compared to HDAC1. HDAC2 
mRNA expression was upregulated by more than 2-fold in 9/16 tumors, compared to 
6/16 for HDAC1. A similar trend was seen at the protein level. Immunohistochemical 
analysis showed that 61.1% of tumors were found to have 2 or 3 grade increase in the 
intensity of HDAC2 staining, compared to 40.3% of tumors for HDAC1. Thus, there 
were significantly more tumor samples with at least a 2-grade increase in intensity for 
HDAC2 staining compared to HDAC1 (p<0.05).  
Interestingly, the upregulation of HDAC2 was observed in colonic polyps, 
suggesting that the change occurred early in the carcinogenic process. The transition 
from polyp to carcinoma was also accompanied by a further increase in HDAC2 mRNA 
expression in all 5 polyps examined. In contrast, the upregulation of HDAC1 was not as 
robust in polyps. Only 2 of the 5 polyps showed an increase in expression in HDAC1 
compared to matched normal mucosa. Further, only 2 of the 5 polyps showed a change 
in HDAC1 expression when compared to matched colonic tumors. This suggests that 
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despite being highly homologous, HDAC1 and HDAC2 may be regulated differently in 
colorectal polyps and colorectal carcinoma. 
The different regulation of HDAC1 and HDAC2 in cancer is consistent with the 
proposal that they have distinct functions in the cell. Lagger et al. (Lagger et al., 2002), 
used HDAC1-deficient mouse embryonic stem cells and showed that HDAC1 possessed 
a unique function which could not be compensated by HDAC2. A separate study 
showed that HDAC1 and HDAC2 have distinct functions in senescence (Wagner et al., 
2001).   
This study also highlights the variations in HDAC1 and HDAC2 expression in 
normal tissue and cancer. This was particularly apparent in the immunohistochemistry 
study using tissue microarray (TMA). The normal mucosal staining intensities for 
HDAC1 ranged from grades 0 to 3, while HDAC2 from grades 0 to 2. The tumor 
staining intensities were also widely distributed although they were skewed towards the 
higher staining intensities. It is only when the relative staining intensities of matched 
samples were compared that the increase in expression in cancer for both HDAC1 and 
HDAC2 became apparent. It is therefore, not surprising that the differences in HDAC 
expression in cancer was not detected in an analysis using non-matched samples (De 
Ruijter et al., 2003) .  
The results from this study suggest that an increase in HDAC activity, especially 
that of HDAC2, facilitates the development of tumors. A study carried out by Zhu et. 
al.(Zhu et al., 2004), showed that HDAC2 overexpression protects cells against 
apoptosis. The protection of cells against apoptosis by HDAC2 may be an important 
factor facilitating the development of tumors. These results suggest that the upregulation 
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of HDAC2 is a cause, rather than a consequence of carcinogenesis. Consistent with its 
role in carcinogenesis, HDAC2 expression was upregulated early in this process, at the 
polyp stage. This proposal is consistent with studies showing that the inhibition of  
HDAC activity using a variety of  inhibitors reverses the cancer phenotype by causing 
cell differentiation (Johnstone, 2002; Kosugi et al., 1999; Kramer et al., 2001; Marks et 
al., 2001; Marks et al., 2000), apoptosis (Glick et al., 1999; Kwon et al., 2002; Ruefli et 
al., 2001; Vrana et al., 1999; Weidle and Grossmann, 2000) and cell cycle arrest (Finzer 
et al., 2001; Sandor et al., 2000). However, since the inhibitors used were not specific 
for any particular HDAC isoform, it has not been possible to determine the functional 
significance of these isoforms in cancer development. Our results indicate that the 
specific HDAC isoform HDAC2 plays an important role in colon cancer development. 
In conclusion, the study has shown that the expression of HDACs1 and 2 is 
increased in colorectal polyp and cancer. The upregulation of HDAC2 expression was 
more robust and occurred more frequently in colorectal tumors. The upregulation 
occurred at the polyp stage, .ie. an early phase in colorectal cancer development. The 
study suggests that histone deacetylases, especially HDAC2, are important markers for 
cancer progression and candidate targets for drug therapy. 
4.2 Characterisation of HCT116 and its derivative cell lines 
The metastastic cell lines were derived from parental HCT116 cell line using a in 
vivo selection method employed in the study by Morikawa et. al.(Morikawa et al., 
1988a). In that study, a set of cell lines with increasing metastatic ability were derived 
through several successive in vivo selection cycles. The group also reported that the 
ability of the injected cells to produce liver metastasis was not due to the cells being 
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simply trapped in the liver. This conclusion was reached after monitoring the in vivo 
distribution of the injected cells. Prior to injection, the cells were labeled with 
[125I]IdUdR to allow for their monitoring. The group discovered that a similar number of 
cells from either the low or the highly metastatic lines reached the liver shortly after 
injection. However, only the highly metastatic cells were able to survive 72 hours after 
injection. Hence they demonstrated that the nude mouse model is a useful tool for 
isolating highly metastatic cells. They also concluded that the ability of cells to survive 
and grow in the liver environment is a crucial factor in determining their metastatic 
potential. 
Our group has applied the same in vivo selection method described by Morikawa 
et al on poorly metastatic HCT116 cells, to generate a set of cell lines with increasing 
metastatic propensity. This work has been carried out by a previous graduate student. 
The parental and derivative cell lines were then further characterised in in vitro and in 
vivo systems. 
During the generation of the metastatic variants, it was observed that the 
resulting number of liver metastases increased with each successive in vivo passaging. 
Subsequent independent in vivo validation of the established lines yielded similar 
results. The increase in metastatic ability is more apparent in the early rounds of in vivo 
passages, with a higher increase in number of liver metastasis nodules from HCT116 to 
M1 and M1 to M2.  There was no appreciable increase in the number of liver metastasis 
nodules obtained in the M3-injected mice compared to those injected with M2.  
Mouse models have become an integral part of cancer research, successfully 
revealing several key molecular players in the development and progression of the 
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disease. The identification of RhoC as an essential player in pulmonary metastasis of 
melanoma cells (Clark et al., 2000), and osteopontin and IL11 in bone metastasis of 
breast cancer cells are just a few of the examples (Kang et al., 2003). There were 
however a few limitations encountered in the system used in this study. Firstly, the 
procedure of doing an orthotopic implantation of colon cancer cells in mice is 
technically challenging, hence the splenic route was chosen. This meant that some early 
putative steps in the metastatic process might not have been recapitulated. Indeed, 
Morikawa et al (Morikawa et al., 1988b) reported differences in the metastatic potential 
of cells derived from injection via splenic route compared to that of orthotopic 
implantation. One cycle of orthotopic implantation in vivo passaging was able to 
produce the same metastatic potential as cells obtained in a four-cycle splenic route of in 
vivo passaging. But the group acknowledged that obtaining metastasis from orthotopic 
implantation was a rare event. Secondly, the use of athymic Balb/C mice in this model 
meant that the whole process occurred in the absence of an intact immune environment. 
Thus some aspects that the host immune system play in the process may not be 
identified. In breast cancer research, it has been possible to perform an orthotopic 
implantation of breast cancer cells in the mammary fat pad of a wild-type Balb/C mouse, 
hence recapitulating most of the putative steps of the metastasis process. However, there 
has so far been no report of successful orthotopic implantation of colon cancer cells in a 
wild-type Balb/C athymic mouse. 
The derived cell lines were found to have a relatively similar morphology as 
their parental HCT116 line, except for the E1 clonal line. E1 cells have a fibroblastoid 
morphology reminiscent of EMT. This morphology was maintained even after many 
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vitro passages as well as in high density cell cultures. EMT was first described in 1908 
by Frank Lillie but only gained acceptance as a distinct process in the 1980s (Greenburg 
and Hay, 1982). EMT has now been recognised as an integral part in the morphogenesis 
of multicellular organisms. The role that EMT play in carcinoma progression was only 
revealed in the recent decade. EMT is now implicated in the dedifferentiation process 
that gives rise to malignant carcinoma as well as dissemination of single carcinoma cells 
from the primary tumour site. Hence the morphology seen in the E1 clonal line is 
amenable to further charaterisation and analysis.  
C1 and E1 clonal lines were found to be the two most invasive line in in vitro 
invasion assays. Interestingly, these two clones were found to have a relatively slower 
proliferation rate compared to the rest of the cell lines. This is a contrast to reports which 
described higher proliferation rate of cells at the invasive front (Dissanayake et al., 
2003). The observation seen in the low-cluster plate experiment was worth noting. There 
seemed to be a general reduction in cell-to-cell interaction as the cells gained a 
metastatic phenotype. This is consistent with reports describing an inverse correlation of 
cell-to-cell interaction and invasiveness (Birchmeier and Behrens, 1994; Koenig et al., 
2006; Perl et al., 1998; Vleminckx et al., 1991). 
4.3 Microarray analysis of HCT116 and its derivative cell lines 
The progression to invasion and metastasis in colorectal tumors appears to 
involve primarily cells at the invasive front (Brabletz et al., 2005). Hence, a global 
transcriptome analysis of whole tumor samples may obscure important genetic 
alterations that occur in the minority of cells within a tumour. Performing gene profiling 
on cell lines instead of tumour tissue mass may circumvent this shortcoming. Moreover, 
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the seven metastatic variant lines obtained in this model were all derived from the same 
origin, the parental HCT116 line. This gave an added advantage as differences in gene 
expression pattern between the parental line and the metastatic derivatives may provide 
clues to actual gene changes that occurred as they gained metastatic phenotype.  
The heterogeneity of a tumour population has been described. The paper 
whereby the HCT116 cell line was first mentioned, described the existence of 
subpopulations with different degrees of tumourigenicity even though they were all 
derived from a primary cell culture of a single human colonic carcinoma (Brattain et al., 
1981). Hence the striking differences observed in the expression profiles of the three 
clonal lines, C1, D1 and E1 and the M3 line from which they were all derived, is 
consistent with the heterogeneity of tumors. The unique expression profiles of C1, D1, 
E1 were not seen in the M3 line as they may only represent a small subpopulation within 
the heterogenous M3 line. In other words, their unique expression profiles were 
obscured by the majority expression profile.  
The change in the expression profile in M1 meant that one cycle of in vivo 
passaging was sufficient to bring about changes in the gene expression. Moreover, the 
M1 expression pattern was generally maintained in the M2 and M3 lines, without any 
further appreciable changes seen. The gene expression of clonal E1 line, with its unique 
EMT-like phenotype and increased invasiveness, is amenable to further analysis, as it 
may reveal key genes responsible for the phenotypical and functional changes. 
The strong correlation between the microarray results and the validation 
performed on qRT-PCR provided us with greater confidence in the data generated by the 
global profiling. S100A4 was chosen as one of the validated genes due to its strong link 
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to metastasis (reviewed in (Garrett et al., 2006)). Caveolin-1 as a candidate metastasis 
suppressor gene in colon cancer 
The study focused on Cav-1 which was downregulated in the metastatic M3 cell 
line and interestingly, its expression was least in the most invasive cell lines, C1 and E1. 
Cav-1 is an essential protein in caveolae structures (Williams and Lisanti, 2005). 
Caveolae are Ω-shaped plasmalemmal invaginations that compartmentalise signaling 
molecules involved in protein trafficking, signal transduction and cholesterol 
homeostasis. Cav-1 was chosen as the focus of this study as it has also been linked to the 
regulation of the Wnt/β-catenin pathway (Galbiati et al., 2000; Lu et al., 2003; Lu and 
Hunter, 2004), which is required for self-renewal of normal intestinal epithelial stem 
cells and is dysregulated in colorectal cancer and cell invasion (Pinto and Clevers, 
2005a; Pinto and Clevers, 2005b).  
Thy hypothesis of this study was that caveolae and Cav-1 may play a role in cell 
migration/invasion by controlling cell membrane composition, polarization of signaling 
molecules, extracellular matrix proteolysis and/or cytoskeleton remodeling (Navarro et 
al., 2004). The down-regulation of Cav-1 mRNA was confirmed in the metastatic cells 
lines by qRT-PCR. Expression of Cav-1 at the protein level was consistent with its 
regulation at the mRNA level. The correlation between Cav-1 expression and metastasis 
was extended to clinical samples. This study utilised matched samples for the expression 
analysis, to take into account the variation in Cav-1 expression observed in the normal 
samples. The down-regulation of Cav-1 in metastatic samples was confirmed by an 
immunohistochemical analysis of 16 matched samples. The downregulation of Cav-1 in 
the metastatic samples was found to be statistically significant (p<0.01).  
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The correlation between the down-regulation of Cav-1 expression and metastasis 
prompted us to examine the role of Cav-1 in metastasis. Since Cav-1 was most down-
regulated in the most invasive cell lines (C1 and E1), this study focused on the possible 
role of Cav-1 in cell invasion. The most invasive line, E1, expressed the lowest levels of 
Cav-1. Transfection of Cav-1 into the E1 line significantly reduced cell invasion, 
suggesting that the reduction of Cav-1 expression in the E1 cells plays a role in 
promoting cell invasion. This anti-invasion activity of Cav-1 is consistent with its 
function in human breast cancer MCF-7 cells, where its over-expression has been shown 
to inhibit soft agar growth, matrix invasion and collagenolytic activity (Fiucci et al., 
2002). Cav-1 was also reported to suppress pulmonary metastasis from primary 
mammary tumors (Williams et al., 2004). However, there are reports correlating the 
increased expression of Cav-1 to metastasis and invasiveness in prostate cancer cells in 
mice and poor prognosis in human prostate cancer (Li et al., 2001; Tahir et al., 2001; 
Yang et al., 1998; Yang et al., 1999). Increased Cav-1 expression was also found to be 
correlated with increased metastatic potential in LoVo colon carcinoma cells (Bender et 
al., 2000), lung adenocarcinoma cells and the presence of lung adenocarcinoma 
metastases in patients (Ho et al., 2002). It is likely that the function of Cav-1 is context 
dependent, constrained by cell-type specificity, proteins recruited to the caveolae and 
signaling pathways operating in the cell.  
4.4 Future directions 
The in vitro results describing Caveolin-1 as a candidate metastasis suppressor 
gene merit further investigation. It is essential to perform the in vivo characterization of 
Cav-1 before it can be confirmed as a metastasis suppressor gene, in the context of colon 
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cancer. Stable Cav-1-expressing E1 cells will be carried out and tested in the in vivo 
system. E1 cells that stably express red fluorescent protein (RFP) have previously been 
generated in the laboratory. These cells will be utilised to create the stable Cav-1 
expressing E1 cells as this will allow easy in vivo monitoring of the cancer progression 
without having to surgically open or sacrifice the mice prematurely (Hoffman, 2005; 
Yang et al., 2000). The mechanism of Cav-1 regulation in the E1 clonal line will also be 
studied. One paper reported that aberrant methylation of Cav-1 promoter was less likely 
to be the common mechanism of epigenetic silencing of the gene in colorectal cancers 
(Lin et al., 2004). A further investigation will be carried out to unravel the mechanisms 
that regulate Cav-1 expression in the E1 line. 
The EMT-like characteristics observed in the E1 clonal line will also be further 
characterised. Preliminary results have revealed that there was no downregulation or 
loss of E-cadherin expression in the E1 cells (data not shown). The loss of E-cadherin 
expression is one of the hallmarks of the EMT process (Grunert et al., 2003). Hence the 
probable EMT phenotype seen in the E1 cells may involve other mechanisms. An 
understanding into the regulation of the EMT phenotype seen in E1 will give an insight 
into ways by which this process may be reversed. Observations can then be made to 
study if EMT reversion alters the invasiveness and metastatic ability of the E1 line. 
Further analysis into the potential interactions between the genes identified from 
the microarray data will be carried out, as this will aid in the mapping of novel pathways 
involved in  colon cancer metastasis, which to-date has not been well characterised.
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